{"id":"inhalation-of-corticosteroids","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Oral candidiasis (thrush)"},{"rate":"5-10","effect":"Hoarseness"},{"rate":"5-15","effect":"Throat irritation"},{"rate":"5-10","effect":"Cough"},{"rate":"1-5","effect":"Dysphonia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Corticosteroids are potent anti-inflammatory agents that work by entering cells and binding to intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene expression. This leads to decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and reduced recruitment and activation of immune cells in the airways. Inhalation delivery targets the drug directly to the lungs, maximizing local efficacy while minimizing systemic exposure.","oneSentence":"Inhaled corticosteroids reduce airway inflammation by binding to glucocorticoid receptors in lung tissue, suppressing inflammatory cytokine production and immune cell activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:48:58.749Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma (maintenance and control)"},{"name":"Chronic obstructive pulmonary disease (COPD)"},{"name":"Allergic rhinitis with lower airway involvement"}]},"trialDetails":[{"nctId":"NCT06372496","phase":"PHASE4","title":"Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-04-16","conditions":"Asthma","enrollment":1366},{"nctId":"NCT06712563","phase":"","title":"Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-04-17","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2000},{"nctId":"NCT04157361","phase":"","title":"Pulmonary Condensate: Non-invasive Evaluation of Pulmonary Involvement in Asthma and Cystic Fibrosis.","status":"RECRUITING","sponsor":"The Institute of Molecular and Translational Medicine, Czech Republic","startDate":"2015-05-01","conditions":"Bronchial Asthma, Pulmonary Cystic Fibrosis","enrollment":450},{"nctId":"NCT05935332","phase":"PHASE2","title":"Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma","status":"TERMINATED","sponsor":"RAPT Therapeutics, Inc.","startDate":"2023-07-05","conditions":"Asthma","enrollment":38},{"nctId":"NCT03822780","phase":"NA","title":"Hydroxychloroquin (HCQ) in chILD of Genetic Defect","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2017-07-01","conditions":"Surfactant Dysfunction","enrollment":25},{"nctId":"NCT06750289","phase":"PHASE3","title":"Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-28","conditions":"Eosinophilic Asthma","enrollment":400},{"nctId":"NCT07073950","phase":"PHASE4","title":"A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-24","conditions":"Chronic Obstructive Pulmonary Disease, Hyperinflation","enrollment":56},{"nctId":"NCT01577082","phase":"PHASE3","title":"Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-04-20","conditions":"Asthma","enrollment":542},{"nctId":"NCT05677139","phase":"","title":"A Study for Observing Severe Asthma in Patients Treated With Tezepelumab","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-12-13","conditions":"Asthma","enrollment":513},{"nctId":"NCT04488081","phase":"PHASE2","title":"I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2020-07-31","conditions":"COVID-19","enrollment":1500},{"nctId":"NCT06596512","phase":"NA","title":"Improving the Quality of Care for Asthma Patients at Risk of Exacerbations","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-07","conditions":"Asthma, Asthma Chronic, Asthma Severe Persistent With Exacerbation","enrollment":4100},{"nctId":"NCT03953300","phase":"PHASE4","title":"Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-10-08","conditions":"Asthma","enrollment":75},{"nctId":"NCT06419413","phase":"","title":"A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-01-08","conditions":"Asthma","enrollment":355},{"nctId":"NCT05807048","phase":"PHASE2","title":"Daratumumab in STK11 Mutated NSCLC","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2023-06-01","conditions":"Non-small Cell Lung Cancer With STK11/LKB1 Mutation","enrollment":8},{"nctId":"NCT07267130","phase":"PHASE1","title":"A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.","startDate":"2025-11-25","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":57},{"nctId":"NCT06307665","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-05-20","conditions":"Asthma","enrollment":440},{"nctId":"NCT06932263","phase":"PHASE2","title":"Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-26","conditions":"Asthma","enrollment":540},{"nctId":"NCT07447739","phase":"PHASE2","title":"Can Betamethasone Given After Birth Help Extremely Premature Babies Come Off Breathing Support Safely and Effectively?","status":"NOT_YET_RECRUITING","sponsor":"Khang Nguyen","startDate":"2026-04","conditions":"Respiratory Distress Syndrome (RDS), Bronchopulmonary Dysplasia (BPD)","enrollment":100},{"nctId":"NCT02476825","phase":"PHASE4","title":"A Bronchoscopy Study to Assess the Effects of Inhaled Corticosteroids on Adult Healthy Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospitals, Leicester","startDate":"2016-01-20","conditions":"Healthy","enrollment":30},{"nctId":"NCT06948396","phase":"","title":"Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-25","conditions":"Asthma","enrollment":300},{"nctId":"NCT03963167","phase":"","title":"Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)","status":"COMPLETED","sponsor":"Chiesi Italia","startDate":"2019-08-21","conditions":"COPD","enrollment":661},{"nctId":"NCT05440851","phase":"NA","title":"Platform of Randomized Adaptive Clinical Trials in Critical Illness","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-04-30","conditions":"Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High","enrollment":6250},{"nctId":"NCT05888350","phase":"NA","title":"Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough.","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2023-04-01","conditions":"Cough","enrollment":502},{"nctId":"NCT07406048","phase":"","title":"Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients","status":"NOT_YET_RECRUITING","sponsor":"Chiesi Farmaceutica Ltda.","startDate":"2026-01-30","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":396},{"nctId":"NCT05922761","phase":"PHASE2","title":"BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-05-31","conditions":"Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases","enrollment":45},{"nctId":"NCT03656926","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":"Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection","enrollment":169},{"nctId":"NCT07396987","phase":"NA","title":"Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation","status":"NOT_YET_RECRUITING","sponsor":"Juan Carlos Cardet","startDate":"2026-02","conditions":"Asthma Attack, Asthma Control, Asthma Exacerbations","enrollment":40},{"nctId":"NCT07396311","phase":"","title":"Fractional Exhaled Nitric Oxide and Exacerbations of COPD","status":"NOT_YET_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2026-03-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":120},{"nctId":"NCT06572228","phase":"PHASE4","title":"Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-08-26","conditions":"Asthma","enrollment":250},{"nctId":"NCT04157348","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-10-29","conditions":"Eosinophilic Granulomatous Vasculitis","enrollment":140},{"nctId":"NCT05341726","phase":"NA","title":"BREATHE: An Efficacy-implementation Trial Among Black Adults With Uncontrolled Asthma","status":"RECRUITING","sponsor":"Columbia University","startDate":"2023-01-19","conditions":"Asthma","enrollment":400},{"nctId":"NCT07372573","phase":"NA","title":"Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler","status":"NOT_YET_RECRUITING","sponsor":"University of Health Sciences Lahore","startDate":"2026-02-01","conditions":"Asthma (Diagnosis)","enrollment":210},{"nctId":"NCT04481555","phase":"PHASE4","title":"Eosinophil-guided Reduction of Inhaled Corticosteroids","status":"COMPLETED","sponsor":"Chronic Obstructive Pulmonary Disease Trial Network, Denmark","startDate":"2021-06-28","conditions":"COPD, Inhaled Corticosteroid, Azithromycin","enrollment":444},{"nctId":"NCT07351916","phase":"","title":"Remission in Adults With Mild-to-moderate Asthma in Thailand","status":"NOT_YET_RECRUITING","sponsor":"Thammasat University","startDate":"2026-02-01","conditions":"Asthma, Mild-to-moderate Asthma, Asthma Control Level","enrollment":289},{"nctId":"NCT07362667","phase":"","title":"A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA","status":"RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2026-01-10","conditions":"ABPA, Allergic Bronchopulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA)","enrollment":44},{"nctId":"NCT07362693","phase":"","title":"A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA","status":"NOT_YET_RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2025-12-31","conditions":"ABPA, Biologics, Allergic Bronchopulmonary Aspergillosis (ABPA)","enrollment":50},{"nctId":"NCT00203684","phase":"PHASE1","title":"Mentored Patient-Oriented Research Career Development Award","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"","conditions":"Asthma, Distal Lung Inflammation","enrollment":57},{"nctId":"NCT06429475","phase":"PHASE3","title":"Anti-Inflammatory Reliever South Africa","status":"RECRUITING","sponsor":"University of KwaZulu","startDate":"2024-06-06","conditions":"Asthma","enrollment":1038},{"nctId":"NCT07328035","phase":"","title":"Remission in Adults With Severe Asthma in Thailand","status":"NOT_YET_RECRUITING","sponsor":"Thammasat University","startDate":"2026-01-01","conditions":"Severe Asthma, Asthma Control Level","enrollment":230},{"nctId":"NCT07329946","phase":"NA","title":"Immuno-inflammatory Response of Erdosteine in COPD","status":"NOT_YET_RECRUITING","sponsor":"Pierachille Santus, MD, PhD","startDate":"2026-02-28","conditions":"COPD","enrollment":30},{"nctId":"NCT05607719","phase":"PHASE2","title":"Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD","status":"RECRUITING","sponsor":"University of Miami","startDate":"2023-04-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":30},{"nctId":"NCT07315555","phase":"NA","title":"Efficacy of Oral Nigella Sativa as Adjuvant Therapy in Children With Moderate Persistent Asthma","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-01-01","conditions":"Community Acquired Pneumonia","enrollment":90},{"nctId":"NCT06422689","phase":"PHASE4","title":"Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-05-10","conditions":"Asthma","enrollment":1507},{"nctId":"NCT06029595","phase":"PHASE2","title":"Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-11-26","conditions":"Uncontrolled Asthma","enrollment":517},{"nctId":"NCT06110403","phase":"PHASE1, PHASE2","title":"Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2023-09-29","conditions":"Copd","enrollment":35},{"nctId":"NCT07288827","phase":"NA","title":"Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia","status":"RECRUITING","sponsor":"Indiana University","startDate":"2023-05-04","conditions":"Primary Ciliary Dyskinesia, Healthy","enrollment":40},{"nctId":"NCT05274815","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-05-17","conditions":"Asthma","enrollment":305},{"nctId":"NCT06027606","phase":"PHASE1","title":"Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2023-09-01","conditions":"Healthy","enrollment":81},{"nctId":"NCT06279078","phase":"","title":"Long-term Effect of Steroid on Metabolic Diseases in Asthmatics","status":"COMPLETED","sponsor":"Ajou University School of Medicine","startDate":"2023-12-30","conditions":"Asthma, Osteoporosis, Osteopenia, Osteoporosis Risk","enrollment":19968},{"nctId":"NCT05832437","phase":"NA","title":"BREATHE-Peds Pilot- II III Trial and Post Trial","status":"COMPLETED","sponsor":"Columbia University","startDate":"2023-05-04","conditions":"Asthma in Children","enrollment":67},{"nctId":"NCT04885530","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2021-06-08","conditions":"Covid19","enrollment":10956},{"nctId":"NCT07052942","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care (Full Study)","status":"RECRUITING","sponsor":"DARTNet Institute","startDate":"2025-08-01","conditions":"Asthma, Asthma Attack, Asthma Exacerbations","enrollment":3200},{"nctId":"NCT03657342","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":"Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection","enrollment":62},{"nctId":"NCT07191535","phase":"PHASE2","title":"Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia)","status":"NOT_YET_RECRUITING","sponsor":"Foresee Pharmaceuticals Co., Ltd.","startDate":"2026-01-01","conditions":"Asthma (Diagnosis), Pulmonary Function, Moderate-to-Severe Asthma","enrollment":135},{"nctId":"NCT04718389","phase":"PHASE3","title":"A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-26","conditions":"Asthma","enrollment":1719},{"nctId":"NCT05329194","phase":"PHASE4","title":"Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-04-29","conditions":"Asthma","enrollment":287},{"nctId":"NCT06795906","phase":"PHASE1","title":"A Safety, Pharmacokinetic, and Pharmacodynamic Study of Once Daily Inhaled AZD8630 in Adults With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-01-28","conditions":"Asthma","enrollment":24},{"nctId":"NCT07198880","phase":"NA","title":"Impact of Home Non Invasive Ventilation in Patients With Chronic Obstructive Pulmonary Disease Discharged From Assiut University Hospital","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-01-01","conditions":"COPD, COPD (Chronic Obstructive Pulmonary Disease), Ventilation Therapy","enrollment":40},{"nctId":"NCT05086432","phase":"NA","title":"Sputum Cytometry Guided Management for the Elimination of Chronic Cough in Patients With ILD","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-05-22","conditions":"ILD","enrollment":120},{"nctId":"NCT03784781","phase":"","title":"Type 2 Innate Lymphoid Cells in Severe Pediatric Asthma","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-06-09","conditions":"Severe Asthma","enrollment":""},{"nctId":"NCT07192016","phase":"PHASE4","title":"129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2026-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":60},{"nctId":"NCT02114034","phase":"","title":"Cohort Analysis of Clinical and Biological Severe Childhood Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-11-12","conditions":"Severe Asthma","enrollment":362},{"nctId":"NCT06970080","phase":"PHASE4","title":"Therapeutic Relevance of Abnormal Airway Morphology in Asthma","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-06-02","conditions":"Asthma","enrollment":242},{"nctId":"NCT06991153","phase":"NA","title":"Impact of Lung Boost Device on Ventilatory Functions and Fatigue in Patients With Interstitial Lung Diseases","status":"COMPLETED","sponsor":"Cairo University","startDate":"2025-05-29","conditions":"Interstitial Lung Disease","enrollment":40},{"nctId":"NCT05919394","phase":"PHASE4","title":"Triple vs High Dose Inhaled CORticosteroids","status":"WITHDRAWN","sponsor":"Galaxia Empírica","startDate":"2023-06-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT06858137","phase":"NA","title":"Thread Embedding Acupuncture For Rhinitis Allergy","status":"COMPLETED","sponsor":"University of Medicine and Pharmacy at Ho Chi Minh City","startDate":"2024-12-15","conditions":"Rhinitis Allergic","enrollment":64},{"nctId":"NCT05292586","phase":"PHASE3","title":"A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-08-31","conditions":"Asthma","enrollment":1377},{"nctId":"NCT06623435","phase":"","title":"Real World and Genomic Data Based Asthma Insight Through Network Analysis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-11-07","conditions":"Asthma","enrollment":1073},{"nctId":"NCT05477108","phase":"PHASE1","title":"Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":108},{"nctId":"NCT04643158","phase":"PHASE2","title":"Efficacy and Safety of Inhaled AZD1402 Administered for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-03-12","conditions":"Asthma","enrollment":72},{"nctId":"NCT05569421","phase":"PHASE1","title":"A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-10-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":108},{"nctId":"NCT04053634","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-08-26","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":689},{"nctId":"NCT07131020","phase":"NA","title":"Study on the Mechanism of Yifei Moxibustion Improving Immune Function in COPD Based on Plasma Exosome miRNAs","status":"RECRUITING","sponsor":"Henan University of Traditional Chinese Medicine","startDate":"2024-05-11","conditions":"Stable COPD Patients","enrollment":120},{"nctId":"NCT06340581","phase":"PHASE1","title":"A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2024-10-17","conditions":"Healthy","enrollment":""},{"nctId":"NCT06721247","phase":"PHASE2, PHASE3","title":"Oral Intake of Mg in Controlled Asthmatic Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zagazig University","startDate":"2024-11-02","conditions":"Bronchial Asthma","enrollment":166},{"nctId":"NCT06297668","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-04-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":42},{"nctId":"NCT07114107","phase":"NA","title":"Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-08","conditions":"Atopic Rhinitis, Atopic Asthma","enrollment":200},{"nctId":"NCT05505734","phase":"PHASE3","title":"A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma","status":"COMPLETED","sponsor":"Bond Avillion 2 Development LP","startDate":"2022-09-02","conditions":"Asthma","enrollment":2516},{"nctId":"NCT01718197","phase":"","title":"Severe Asthma Research Program (SARP)- San Francisco Clinical Site","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2012-11","conditions":"Asthma","enrollment":151},{"nctId":"NCT02103348","phase":"","title":"Characterizing Asthma Sputum Elasticity in the UCSF Severe Asthma Research Program","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2015-09","conditions":"Asthma","enrollment":25},{"nctId":"NCT04480242","phase":"","title":"Asthma Research in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2017-07-26","conditions":"Persistent Asthma, Asthma in Children, Asthma Exacerbation","enrollment":525},{"nctId":"NCT05757583","phase":"","title":"Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2023-04-05","conditions":"Asthma","enrollment":80},{"nctId":"NCT04942483","phase":"","title":"Using Tests in Preschool Children With Wheeze to Determine the Need for Inhaled Corticosteroid Therapy.","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2021-11-17","conditions":"Wheezing","enrollment":118},{"nctId":"NCT07058259","phase":"NA","title":"Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul Medeniyet University","startDate":"2024-11-15","conditions":"COPD (Chronic Obstructive Pulmonary Disease), Acupuncture","enrollment":60},{"nctId":"NCT07053839","phase":"NA","title":"Effect of a Daily Text Reminder on Asthma Medication Use, Symptom Control, and Lung Function in Children","status":"COMPLETED","sponsor":"ROXANA AZNARAN TORRES","startDate":"2023-07-22","conditions":"Asthma in Children","enrollment":64},{"nctId":"NCT05819541","phase":"PHASE2","title":"Treating Exacerbations of Asthma With Oral Montelukast in Children","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-10-20","conditions":"Status Asthmaticus","enrollment":90},{"nctId":"NCT06732141","phase":"NA","title":"Remote Anxiety Management for ICS-resistant Asthma Study","status":"RECRUITING","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2024-12-13","conditions":"Asthma","enrollment":216},{"nctId":"NCT07030881","phase":"NA","title":"Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple Therapy","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2025-06-20","conditions":"Asthma, COPD","enrollment":380},{"nctId":"NCT03248128","phase":"PHASE3","title":"Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-10-20","conditions":"Asthma","enrollment":906},{"nctId":"NCT04456673","phase":"PHASE3","title":"Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-07-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":935},{"nctId":"NCT06272370","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care","status":"COMPLETED","sponsor":"DARTNet Institute","startDate":"2024-02-01","conditions":"Asthma, Bronchial Diseases, Respiratory Tract Infections","enrollment":103},{"nctId":"NCT06931899","phase":"","title":"Oscillometry in the COPD Exacerbator Phenotype With Triple Inhaled Therapy Study","status":"NOT_YET_RECRUITING","sponsor":"Hospital Universitari de Bellvitge","startDate":"2025-04","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":63},{"nctId":"NCT03692676","phase":"","title":"Characteristics of Pts Initiating Spiriva Respimat in Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-03-05","conditions":"Asthma","enrollment":116133},{"nctId":"NCT04937543","phase":"PHASE2","title":"Efficacy of Inhaled Therapies in the Treatment of Acute Symptoms Associated With COVID-19","status":"COMPLETED","sponsor":"UPECLIN HC FM Botucatu Unesp","startDate":"2021-06-28","conditions":"Covid19","enrollment":50},{"nctId":"NCT06552364","phase":"PHASE4","title":"Air Pollution and Inhaled Corticosteroids in COPD","status":"NOT_YET_RECRUITING","sponsor":"University of British Columbia","startDate":"2025-04-01","conditions":"COPD","enrollment":48},{"nctId":"NCT05552508","phase":"PHASE4","title":"BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-10-11","conditions":"Asthma","enrollment":45},{"nctId":"NCT03141424","phase":"PHASE4","title":"Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma","status":"COMPLETED","sponsor":"Hvidovre University Hospital","startDate":"2022-06-01","conditions":"Asthma","enrollment":20},{"nctId":"NCT06869382","phase":"PHASE4","title":"ICS+LABA Vs. ICS+LABA+Omalizumab: Impact on Asthma Control and Gene Expression","status":"COMPLETED","sponsor":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","startDate":"2023-01-01","conditions":"Asthma Patients","enrollment":26},{"nctId":"NCT05563675","phase":"PHASE4","title":"Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization or Death from Any Cause","status":"COMPLETED","sponsor":"Chronic Obstructive Pulmonary Disease Trial Network, Denmark","startDate":"2023-01-27","conditions":"COPD Exacerbation","enrollment":10011},{"nctId":"NCT06819462","phase":"NA","title":"Inhaled Polymyxin E to Prevent VAP","status":"NOT_YET_RECRUITING","sponsor":"Southeast University, China","startDate":"2025-02-01","conditions":"Ventilator-Associated Pneumonia (VAP), Inha&#39;le&#39;d","enrollment":434}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"inhalation of corticosteroids","genericName":"inhalation of corticosteroids","companyName":"Soroka University Medical Center","companyId":"soroka-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhaled corticosteroids reduce airway inflammation by binding to glucocorticoid receptors in lung tissue, suppressing inflammatory cytokine production and immune cell activation. Used for Asthma (maintenance and control), Chronic obstructive pulmonary disease (COPD), Allergic rhinitis with lower airway involvement.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}